Agoracom: Small Cap Investment - Zenith Epigenetics - Re: Gilead pays $21B for Immunomedics, a single cancer drug (newly approved) for metastic Triple Negative Breast Cancer

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Back To Forum List View

Gilead pays $21B for Immunomedics, a single cancer drug (newly approved) for metastic Triple Negative Breast Cancer

Payzone

Sep 17, 2020 03:08PM

KOO-KOO2

Rank: Treasurer [?]

Points: 10765 [?]

Votes: 39 Score: 2.3 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: Gilead pays $21B for Immunomedics, a single cancer drug (newly approved) for metastic Triple Negative Breast Cancer

in response to

Gilead pays $21B for Immunomedics, a single cancer drug (newly approved) for metastic Triple Negative Breast Cancer

Payzone

posted on Sep 21, 2020 09:19AM

Perhaps Don would have been better to have kept all things together in 2013 as opposed to going the SPINCO route and put the money on developing a cancer drug as opposed to a cardiovascular drug.

Koo

2 Recommendations

Re: Gilead pays $21B for Immunomedics, a single cancer drug (newly approved) for metastic Triple Negative Breast Cancer

Mazola

Sep 22, 2020 03:03PM

Re: Gilead pays $21B for Immunomedics, a single cancer drug (newly approved) for metastic Triple Negative Breast Cancer

narmac

Sep 22, 2020 07:55PM

Re: Gilead pays $21B for Immunomedics, a single cancer drug (newly approved) for metastic Triple Negative Breast Cancer